A substantial fraction of apparent drug failure reflects mistimed intervention rather than incorrect mechanism. Treatment response depends on system state and timing, not only on pharmacology. Negative results may therefore represent phase mismatch rather than true inefficacy. Many drug candidates fail in late-stage trials, and many approved treatments fail in everyday clinical use. These outcomes are typically interpreted as evidence that the underlying mechanism is incorrect. This paper proposes a different interpretation: that a substantial fraction of apparent drug failure reflects mistimed intervention rather than true inefficacy. From a systems-dynamic perspective, treatment response is not a fixed property of a drug but a relational event between intervention and system state. Disease is understood as an evolving process rather than a static condition, where responsiveness depends on phase, stability, and the system’s capacity for transition. When treatment is applied outside a phase of system plasticity, effects may be weak, delayed, masked, or absent—even when the biological mechanism remains relevant. The paper introduces phase mismatch as a central mechanism underlying apparent treatment failure and shows how this can explain several commonly observed patterns, including non-response, delayed response, and heterogeneous treatment effects. It further examines how randomized controlled trials, by averaging across patients in different dynamic phases, may obscure phase-dependent treatment effects and lead to negative or inconclusive results. The concept of reset windows is presented as a key feature of dynamic disease systems—periods in which system behavior remains modifiable and intervention can alter long-term trajectories. Failure to account for such temporal structure may lead to systematic misinterpretation of both trial outcomes and clinical response. Clinically, this perspective reframes non-response not as a single phenomenon but as a composite of distinct timing states, including late intervention after loss of plasticity, early intervention before system readiness, and compensatory masking by parallel regulatory processes. This has implications for how treatment decisions are interpreted and adjusted in practice. This work is part of the Timing & Failure series and is consistent with the broader framework of the Universal Resonance Model (URM), in which disease progression reflects transitions between dynamic system states. Rather than rejecting existing evidence, the paper proposes a reinterpretation: negative results may not invalidate mechanisms, but instead reflect that interventions were applied at the wrong moment in the system’s trajectory.
Anita Domargård (Sun,) studied this question.